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ABSTRACT
The study comprised 37 consecutive patients who underwent transplantation with a Campath-1H in vitro T
cell–depleted granulocyte colony-stimulating factor–mobilized peripheral blood stem cell graft from an HLA-
identical sibling, followed 24 hours later by an unmanipulated graft. Acute graft-versus-host disease (GVHD)
was limited to grade I to II, whereas chronic graft-versus-host disease occurred in 9 patients, mostly (n  7)
with limited disease. Molecular relapses (8 chronic myeloid leukemia [CML] and 1 non-Hodgkin lymphoma)
that occurred not earlier than the sixth month after transplantation were treated with donor lymphocyte
infusion (DLI), which induced complete remission in all but 1 CML patient with persistent very low BCR-ABL
molecular levels. With a median follow-up of 54 months (range, 29-84 months), the actuarial 5-year overall
survival, disease-free survival, and transplant-related mortality are 78% (95% confidence interval [CI], 52%-
88%), 78% (95% CI, 52%-86%), and 6% (95% CI, 1.5%-32%), respectively. All CML patients are alive and free
of disease. The results of this prospective, nonrandomized study show that incomplete T-cell depletion in vitro
with Campath-1H (in combination with DLI for molecular relapses in CML) may decrease the incidence of
GVHD and transplant-related mortality with no adverse effect on disease-free survival. The described method
decreases the number of T cells to an extent that severe GVHD is prevented while relapse is postponed to a
time when the patient can be treated with DLI without severe side effects.
© 2006 American Society for Blood and Marrow Transplantation
KEY WORDS
Allogeneic stem cell transplantation ● Graft-versus-host disease ● Transplant-related
mortality ● Donor lymphocyte infusion ● Partial in vitro T-cell depletion ● Campath-1H
1
p
o
a
p
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Transplantation with stem cells from an HLA-
dentical sibling donor is a well-established therapeu-
ic modality for hematologic malignancies [1]. Trans-
lant-related mortality (TRM) is a major factor that
nﬂuences the outcome of allogeneic hematopoietic stem
ell transplantation, with an incidence that ranges from u
020% to 50%, depending on the disease and age of the
atient and on the type of treatment [2-10]. The type
f treatment can be modiﬁed by adapting the prepar-
tive regimen, graft-versus-host disease (GVHD) pro-
hylaxis, and supportive therapy to the biologic char-
cteristics of the patient and the condition of the
nderlying disease [11].
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Partial T-Cell Depletion in Allogeneic Transplantation
BMature donor T cells in the graft may cause severe
orms of GVHD, a major cause of mortality after
ematopoietic stem cell transplantation (HSCT) [12].
-cell depletion diminishes this risk but is associated
ith an increased frequency of relapse or graft failure,
o the outcome is not different from that for HSCT
ith unmanipulated grafts [10,13-19].
Peripheral blood stem cells (PBSCs) are often
sed as an alternative to bone marrow [20-27]. Trans-
lantation with PBSCs is associated with a more rapid
latelet and neutrophil recovery [24-27] and possibly
lso with a better survival in patients with advanced
eukemia [27,28]. However, it is still under debate
hether good-risk patients with low relapse rates who
ndergo transplantation with PBSCs could be at a
igher risk of GVHD. With the exception of a recent
uropean Group for Blood and Marrow Transplan-
ation trial [29], most studies have shown identical
ncidences of acute GVHD (aGVHD) [25-28,30]. In
ontrast, the incidence of chronic GVHD (cGVHD)
ay be higher with PBSC transplantation [26,28,29,31],
lthough this ﬁnding has not been conﬁrmed by others
25,27,30].
PBSC grafts contain more nucleated cells and
D34 cells and 1 order of magnitude more T and
atural killer cells than do bone marrow grafts [32].
epleting T cells from the graft is known, however, to
ncrease the risk of relapse. The monoclonal anti-
D52 antibody Campath (Therapeutic Antibody
entre, University of Oxford, UK) has long been used
or T-cell depletion [14,33-37]. The initial experience
ith Campath-1M in vitro resulted in a high inci-
ence of graft failure, but the risk was reduced by
sing Campath-1G in vivo [19]. Other groups did not
nd a difference regarding the incidence of graft fail-
re between Campath-1M and -1G, but patients re-
eived total lymphoid irradiation as part of the condi-
ioning regimen for further immunosuppression and
revention of rejection [36,37]. Improved survival has
een shown by using Campath-1G in vitro for PBSC
rafts compared with unmanipulated PBSC infusions
38]. Recently, promising results in a small series of
atched related allogeneic PBSC transplant patients
ere obtained with Campath-1H, the humanized
orm of this antibody, in vitro [39]. The incidence of
GVHD and cGVHD was 8.7% and 4.4%, respec-
ively, and TRM was 19.1%, but the incidence of
elapse was still high (48.7%).
In our single-center prospective study, we tested a
rotocol of partial T-cell depletion with Campath-1H
n combination with donor lymphocyte infusion (DLI)
or molecular relapses in chronic myeloid leukemia
CML). The strategy used was to ﬁrst administer an in
itro T cell–depleted graft of PBSCs consisting of 2
ooled aphereses incubated with Campath-1H for 30
inutes and then washed before infusion into the
atient. A third unmanipulated apheresis that con- g
B&MTained approximately a third of the total number of T
ells was given the next day to prevent graft failure and
o decrease the risk of relapse. The residual Cam-
ath-1H contained in the ﬁrst pooled aphereses did
ot signiﬁcantly inﬂuence the T-cell content of the
econd unmanipulated apheresis infused 24 hours
ater. We show that this protocol may decrease the
ncidence of GVHD and TRM with no adverse effect
n disease-free survival (DFS), but at the cost of DLI
or molecular relapse in most patients with CML. In
his limited collective, no effect on the relapse rate for
cute myeloid leukemia (AML) patients was noticed.
ATIENTS AND METHODS
atients
Between January 1998 and August 2002, 37 suc-
essive patients with hematologic diseases received
llogeneic PBSC transplants from an HLA-identical
ibling at the bone marrow transplantation (BMT)
nit of Geneva University Hospital. All patients gave
heir informed consent, and all the research studies
ere approved by the university and the institutional
eview boards.
onditioning Regimens
Most patients (n  31) received cyclophospha-
ide (CY) combined with fractionated total body ir-
adiation (TBI) (CY 60 mg/kg intravenously [IV] days
6 and 5, followed by fractionated TBI [1000 cGy
or patients 40 years old or 1200 cGy for younger
atients] [40]) with or without methylprednisolone
MP) 1 g/m2 days 2 and 1 for a total of 3 doses (19
atients with CML, aplastic anemia, multiple my-
loma, lymphoma, or myelodysplastic syndrome) with
r without antithymocyte globulin (12 patients with
ML and aplastic anemia received antithymocyte glob-
lin in order to decrease the risk of rejection). Three
atients received a busulfan (BU)–based regimen (BU
mg/kg by mouth every 6 hours days 7 to 4 and
Y 60 mg/kg IV days 3 and 2, or etoposide 60
g/kg). Two patients received etoposide (60 mg/kg)
ombined with TBI or BU and MP. One patient with
evere aplastic anemia received CY combined with
P and antithymocyte globulin. Patients receiving
U were given clonazepam as seizure prophylaxis.
roepithelial prophylaxis with hyperhydration and
ontinuous perfusion of mesna was administered dur-
ng CY infusion and for 24 hours after the last dose of
Y (Table 1).
BSC Collection and GVHD Prophylaxis
Mobilized PBSCs were collected with a Cobe
pectra (Cobe Laboratories Inc., Lakewood, CO) cell
eparator on days 4, 5, and 6 after stimulation with
ranulocyte colony-stimulating factor (lenograstim
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10 g/kg/d; Granocyte; Aventis Pharma AG, Zürich,
witzerland). The graft was analyzed to assess the
umber of hematopoietic progenitors (CD34 cells)
nd CD3 cells by using standard ﬂow cytometry
rocedures and colony assay (colony-forming unit–
ranulocyte macrophage). Partial in vitro T-cell de-
letion was performed by treatment of the pooled day
and 5 aphereses with 20 mg of humanized anti-
D52 (Campath-1H produced by the Therapeutic
ntibody Centre, University of Oxford, Oxford, UK,
ourtesy of Geoff Hale and Hermann Waldmann)
41] incubated for 30 minutes and then washed by
entrifugation before infusion on day 0. The next day
day 1), the day 6 apheresis was infused unmanipu-
ated. Details of the different GVHD prophylaxis reg-
mens are outlined in Table 1. Most patients received
yclosporin and short-course methotrexate 15 mg/m2
ay 1 and 10 mg/m2 days 3 and 6 [42,43]. Treatment
f established aGVHD was with prednisone. GVHD
as graded according to standard criteria [44].
upportive Care
Patients were treated at the BMT unit of the
able 1. Patient Characteristics (n  37)
Characteristic Data
edian age, y (range) 40 (18-60)
ex (M/F) 21 (57%)/16 (43%)
iagnosis, n (%)
CML 11 (30)
AML 12 (32)
ALL 2 (5)
MDS 3 (8)
Lymphoma 5 (14)
AA 2 (5)
MM 2 (5)
isk status (SR/HR) 23 (62%)/14 (38%)
VHD prophylaxis (CSA  MTX/
CSA) 30 (81%)/7 (19%)
onditioning regimen, n (%)
With cyclophosphamide 34 (92)
With busulfan 3 (8)
With etoposide 2 (5)
BI doses (1200/1000/600 cGy) 21 (57%)/11 (30%)/1 (3%)
MV serostatus, n (%)
R/D 12 (32)
R/D 4 (11)
R/D 4 (11)
R/D 17 (46)
BO incompatibility major, n (%) 8 (22)
BO incompatibility minor, n (%) 4 (11)
ML indicates chronic myeloid leukemia; AML, acute myeloid
leukemia; ALL, acute lymphoid leukemia; MDS, myelodysplas-
tic syndrome; AA, aplastic anemia; MM, multiple myeloma; SR,
standard risk (patients with acute leukemia in ﬁrst complete
remission, with CML in ﬁrst chronic phase, or with AA); HR,
high risk (all the others); CSA, cyclosporin A; MTX, methotrex-
ate; TBI, total body irradiation; CMV, cytomegalovirus; R,
recipient; D, donor.eneva University Hospital in a single isolation room m
04ith laminar air ﬂow. Permanent central catheters
Groshong; Bard Medica SA, Geneva, Switzerland)
ere used routinely. Empiric IV antibiotics, liposomal
mphotericin B (AmBisome; Fresenius Medical Care
G, Stans, Switzerland), acyclovir, ﬁltrated cytomeg-
lovirus (CMV)–negative blood products, and total par-
nteral nutrition were given as required. Fungal prophy-
axis was ﬂuconazole IV 200 mg/d. Pneumocystis carinii
rophylaxis included trimethoprim/sulfamethoxazole
dministered before transplantation and as soon as the
bsolute neutrophil count exceeded 1  109/L. Pa-
ients were screened twice weekly for CMV by pp65
ssay, and, upon positive ﬁndings, preemptive ganci-
lovir therapy was given at a dose of 5 mg/kg IV twice
aily for 14 days and then at 5 mg/kg daily or as
djusted for renal impairment for 2 weeks (or longer
n case of persistent CMV antigenemia) [45]. In case
f neutropenia, foscarnet was given at 90 mg/kg IV
wice daily for 2 weeks and then at 90 mg/kg daily or as
djusted for renal impairment for 2 weeks (or longer in
ase of persistent CMV antigenemia). Growth factors
ere used for drug-induced neutropenia and persis-
ent febrile neutropenia. Low-dose heparin (5000 or
0 000 IU IV continuously for 24 hours according to
atient weight) was given routinely for hepatic veno-
cclusive disease prevention [46]. Starting in October
999, as part of another study, patients also received
eﬁbrotide as veno-occlusive disease prophylaxis [47].
tatistical Analysis
Overall survival (OS), event-free survival (EFS;
elapse or death from whatever cause), DFS (deﬁned
s survival without evidence of disease after DLI [if
ecessary]), transplant-related mortality (TRM), re-
apse, aGVHD, and cGVHD probabilities were cal-
ulated by using the product-limit method of Kaplan
nd Meier [48]; surviving patients were censored on
ecember 15, 2004. Survival curves were compared
y using the log-rank test. Variables are described by
eans of median and range.
ESULTS
atient Characteristics
Patient characteristics are shown in Table 1. All
ML patients and 8 (66%) of 12 AML patients were
n the standard-risk group. All patients received
BSCs partially depleted in vitro with Campath-1H
rom an HLA-identical sibling. Thirty-one patients
84%) received a CY/TBI conditioning regimen, 3
atients received a BU-based regimen, and 2 patients
eceived an etoposide-based regimen. The median
ime from diagnosis to PBSC transplantation was 6
onths (range, 2.5-49 months).
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Partial T-Cell Depletion in Allogeneic Transplantation
Bollection and Characteristics of Hematopoietic
tem Cell Products
The goal of leukapheresis was to harvest a mini-
um of 4  106 CD34 cells per kilogram of recip-
ent body weight. All donors had 3 leukaphereses, but
donors (19%) did not reach the target, and the
orresponding patients received a median of 3.2 106
D34 cells per kilogram of body weight (range, 2.9 
06 to 3.9 106 cells). No serious adverse events were
bserved during PBSC collection.
ngraftment
All patients engrafted successfully. The median time
o neutrophil recovery (absolute neutrophil count of at
east 0.5 Giga/liter or 109/liter [G/L]) was 14 days
range, 8-21 days; Table 2). The median time to plate-
et recovery (at least 50 G/L) was 13.5 days (range,
igure 1. A, Incidence of aGVHD grade I and II (Œ) and grade II
nly (●). B, Incidence of cGVHD (limited and extensive) after
llogeneic PBSC transplantation partially T-cell depleted in vitro
able 2. Engraftment of In Vitro T Cell–Depleted Hematopoietic
tem Cell Allograft with Campath-1H
Variable Median (range)
otal nucleated cells infused (108/kg) 13.2 (5.3-32.3)
D34 cells infused (106/kg) 9.6 (3-49)
FU-GM infused (104/kg) 50 (3-580)
D3 cells infused (106/kg) 111 (23-304)
NC >0.5 G/L (d) 14 (8-21)
latelets >50 G/L (d) 13.5 (8-27)
FU-GM indicates colony-forming unit–granulocyte macrophage;
ANC, absolute neutrophil count Giga/liter or 109/liter (G/L).ith Campath-1H. t
B&MT-27 days). One patient died of infection before neu-
rophil and platelet recovery, at day 9 after transplan-
ation.
ncidence of GVHD
The cumulative incidence of aGVHD grade I and
I was 39% (14 patients) at day 100 after transplan-
ation. Most (11 patients; 79%) had grade I aGVHD,
nd 3 patients had grade II disease (Figure 1A). None
f the patients developed aGVHD grade III or IV.
he cumulative incidence of cGVHD at 5 years after
ransplantation was 26% (9 patients). Most (78%) of
he patients had limited disease (7 patients), 1 patient
ad extensive disease, and 1 patient developed bron-
hiolitis obliterans–organizing pneumonia, with a fa-
orable outcome (Figure 1B).
urvival, Relapse, and TRM
The median follow-up was 54 months (range,
9-84 months for surviving patients). Eight patients
ied (Table 3), and the actuarial 5-year probabilities
igure 2. OS (●) and TRM (Œ) after allogeneic PBSC transplanta-
able 3. Causes of Death in Patients Who Received In Vitro
Cell–Depleted Hematopoietic Stem Cell Allografts with Campath-1H
Status at
Transplantation Cause of Death
Survival Time
(d)
ML CR1 Infection 9
ML CR1 GVHD  infection 223
ML primary IF R/P 94
ML first relapse R/P 191
econdary AML CR1 R/P 488
LBCL CR2 R/P 532
AEBt CR2 R/P 742
M first PR R/P 1369
ML indicates acute myeloid leukemia; RAEBt, refractory anemia
with excess of blasts in transformation; DLBCL, diffuse large
B-cell lymphoma; GVHD, graft-versus-host disease; CR, com-
plete remission; PR, partial remission; IF, induction failure;
R/P, relapse or progression; MM, multiple myeloma.ion partially T-cell depleted in vitro with Campath-1H.
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1or OS (Figure 2) and EFS (Figure 3A) were 78%
95% conﬁdence interval [CI], 52%-88%) and 53%
95% CI, 32%-69%), respectively. The most common
vents were either persistent molecular disease or re-
apse in CML patients. The actuarial 5-year probabil-
ty of relapse (molecular or hematologic) for the entire
roup was 43% (95% CI, 28%-65%; Figure 3B).
espite these molecular relapses, the actuarial 5-year
robability of OS was 100% (95% CI, 44%-100%) for
ML patients. This probability was statistically sig-
iﬁcantly different from that of the rest of the pa-
ients, with an estimated OS at 5 years of 68% (95%
I, 40%-83%; P  .045; Figure 4). Follow-up of
atients with CML was between 44 and 84 months
fter transplantation. Conversely, regarding AML pa-
ients, the other main group of patients who under-
ent transplantation with this protocol (n  12), the
-year probability of relapse was lower than in CML
atients: 28% (95% CI, 2%-54%) as compared with
3% (95% CI, 37%-89%).
For the entire group of patients, the cumulative
ncidence of TRM (2 patients) was 3% at 100 days
95% CI, 0.5%-14%) and 6% at 5 years (95% CI,
.5%-32%) (Figure 2). Because of the low number of
eaths in our patients, we limited our analysis of risk
actors to EFS. There was a trend for a lower EFS in
atients older than 40 years compared with younger
atients (P  .052) and a lower EFS in CML patients
n  11) compared with patients with other diseases
n  26; P  .014). Risk status (P  .98) and CMV
igure 3. EFS (A) and incidence of relapse (B) after allogeneic
BSC transplantation partially T-cell depleted in vitro with Cam-
ath-1H.erostatus (P  .80) had no inﬂuence on EFS. i
06utcome of Relapsing Patients
Ten of ﬁfteen patients who had persistent disease
r who relapsed received DLI. Five patients could not
e treated: 2 patients died of sepsis during reinduction
hemotherapy, 1 had active GVHD at the time of
elapse, 1 had a second transplantation, and 1 with
esidual extrahematopoietic disease at the time of
ransplantation experienced progressive disease imme-
iately after transplantation despite a reduction of
mmunosuppression. The eligible 8 of 11 CML pa-
ients either with persistent molecular residual disease
r in molecular relapse were treated when the BCR-
BL/ABL ratio increased 2 times at 1-month intervals
n 2 consecutive determinations (between 6 and 15
onths [median, 8.5 months] after transplantation).
hey received escalating doses of DLI (ﬁrst dose, 106;
econd dose, 5 106; third dose, 107; fourth dose, 5
07; and up to 108 CD3 T cells per kilogram of body
eight, depending on the response) until a decrease of
he BCR-ABL ratio. The median number of doses
eeded to obtain these results was 3 DLIs (range, 1-6).
After treatment (the median length of follow-up
fter DLI was 16.5 months; range, 6-50 months), 7 of
patients were in complete molecular remission,
hereas 1 patient had persistent molecular residual
isease with a stable BCR-ABL/ABL ratio 0.05%
uring 4 consecutive measurements at least 1 month
part. All patients converted to full donor chimerism a
edian of 7.4 months after DLI (range, 5.8-11.5
onths).
Only 1 of the CML patients experienced GVHD
fter DLI, and it was mild and responded well to
opical therapy. The 2 patients with relapsing multiple
yeloma and non-Hodgkin lymphoma (mantle cell
ymphoma) received higher starting doses of DLI (107
D3 cells per kilogram). The non-Hodgkin lym-
igure 4. OS after allogeneic PBSC transplantation partially T-cell
epleted in vitro with Campath-1H in patients with CML (Œ) and
n patients with other diseases (●).
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Partial T-Cell Depletion in Allogeneic Transplantation
Bhoma patient went into complete remission with
utaneous GVHD after DLI, whereas the patient with
ultiple myeloma died from progression despite treat-
ent. As a whole, the actuarial 5-year probability of DFS
or all patients was 78% (95% CI, 52%-86%; Figure 5),
nd this was 100% (95% CI, 44%-100%) for the
ML patients.
ISCUSSION
Mortality and morbidity related to GVHD remain
igniﬁcant problems after HSCT. T-cell depletion de-
reases the risk of GVHD but increases the risk of
ejection and relapse. The higher relapse rates are due to
he fact that the T cells depleted to prevent GVHD are
lso responsible for the graft-versus-leukemia (GVL)
ffect. Although these 2 phenomena may be insepara-
le, GVL can occur without a manifest GVHD be-
ause, particularly in CML patients, the leukemic cells
re more sensitive to an allogeneic reaction. The
-cell dose that induces GVL without initiating
VHD has been established in animal models [49-51]
ut has unfortunately proven to be much harder to
etermine in humans. At present, 1  105 T cells per
ilogram is considered the critical dose, but the clin-
cal studies in which these doses have been used have
ot yielded consistent results [52-54]. We followed a
ransplantation protocol that consisted of a ﬁrst infu-
ion of PBSCs treated in vitro with Campath-1H
ollowed by an unmanipulated apheresis 24 hours
ater. The main goal was to infuse a minimum of 4 
06 CD34 cells per kilogram to decrease the risk of
ejection and, at the same time, to increase the poten-
ial tolerizing effect associated with high doses of stem
ells [55]. This goal (4  106 CD34 cells per
ilogram) was reached in 80% of the patients, whereas
n the other 20%, the lowest number of CD34 cells
igure 5. DFS after allogeneic PBSC transplantation partially
-cell depleted in vitro with Campath-1H.nfused was 2.9  106 CD34 cells per kilogram. No t
B&MTigns of rejection have been observed, and there was a
ow incidence of aGVHD.
The second goal was to decrease the number of T
ells infused to prevent GVHD to a level that would
till preserve the GVL effect. It should be noted that
ith the protocol used, it is impossible to know exactly
ow many donor T cells persist in the patient after the
infusions. First, not all donor T cells are lysed by the
reatment with Campath-1H in vitro, and it is difﬁcult
o estimate how many will still be lysed after these
ells that are coated with antibody are infused into the
atient. Moreover, even after the second infusion that
ontains the unmanipulated apheresis, with a mean of
29  106 CD3 cells per kilogram, T-cell depletion
ay continue in vivo because at that moment, the
ampath-1H antibody coinfused with the ﬁrst graft is
till present at 0.21  0.07 g/mL, as measured in 5
atients by a Campath-1H–speciﬁc enzyme-linked
mmunosorbent assay.
However, several observations indicate that the
-cell depletion achieved with this protocol (includ-
ng in vivo lysis of the third T cell–replete apheresis by
esidual Campath-1H) is only partial. First, there is a
omewhat noticeable incidence of aGVHD that is, nev-
rtheless, not severe (34% grade I and II aGVHD).
econd, in approximately one third of our patients, some
ecipient T cells persisted for the ﬁrst 1 to 2 months after
ransplantation (data not shown). Therefore, although
he concentration of Campath-1H present at the time
f the last infusion has been reported to be cytolytic
56], its efﬁcacy at these borderline concentrations
0.21  0.07 g/mL) may not be complete. Third,
nd more important, regarding CML patients, this
utative in vivo T-cell depletion may have been in-
omplete because full hematologic relapses during the
rst 6 months were not seen, whereas they occurred
arly in 5 (24%) of 21 CML patients who underwent
ransplantation previously at our institution with com-
letely T cell–depleted grafts and with Campath-1M
n vitro. We believe that this is the most signiﬁcant
dvantage of our protocol, which translates into a high
FS rate with little morbidity. Although the fre-
uency of CML relapses in the recipients of fully and
artially depleted grafts was comparable, none of the
olecular relapses in the CML patients in our current
rotocol occurred earlier than 6 months after trans-
lantation. This allowed us to give the DLI at a time
hen the patient would suffer less from the adverse
ffects of this treatment, thus signiﬁcantly increasing
he chance of success. The lower incidence of DLI-
ssociated GVHD observed in our study may also be
elated to the combination of low starting doses (106
D3 cells per kilogram as compared with 107 CD3
ells per kilogram in the study of Schaap et al. [57])
nd the timing of DLI (started more than 6 months
fter transplantation as compared with 30 days after
ransplantation in the study of Barrett et al. [58] or
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1ven earlier in the study of Naparstek et al. [36]). This
ose- and time-dependent development of GVHD
fter DLI, which enables the use of protocols that
esult in GVL without severe clinical signs of GVHD,
as also been reported by others [55,59-62].
Although not complete, the depletion was efﬁcient
nough to prevent GVHD grade III and IV. This
ompares very favorably to results in patients who
eceived unmanipulated grafts [2,4-6,27,28,30] and is
ot worse than results in patients who received fully T
ell–depleted grafts [10,13-19,39]. The same holds
rue for the occurrence of cGVHD. With only 2
atients experiencing extensive disease or bronchioli-
is obliterans–organizing pneumonia, the results seem
o be signiﬁcantly better than those in protocols with-
ut T-cell depletion [27,28,30].
T cell–depleted allogeneic BMT from an HLA-
dentical sibling for acute leukemia using a slightly
ifferent strategy with Campath-1M in vitro or Cam-
ath-1G “in the bag” followed in a subgroup of pa-
ients by an early administration of DLI (escalating
oses starting on day 1 after transplantation up to
ay 84) was described previously in a larger number
f patients [36]. To decrease rejection, total lymphoid
rradiation was added to the conditioning regimen.
he results were promising, with a leukemia relapse-
ree survival at 2 years of 83% in patients who under-
ent transplantation in ﬁrst complete remission, 76%
n patients who underwent transplantation in second
omplete remission, and 42% in patients who under-
ent transplantation in advanced leukemia. These
ates are comparable to those obtained in this study.
owever, the results did show a higher incidence of
raft failure (6.8% versus 0%) and higher TRM (82
atients [56%] died out of 146 patients who under-
ent transplantation [24 from leukemic relapse and
he rest from graft failure or TRM], versus 6% TRM
t 5 years in our study). Moreover, with the strategy of
arly DLI, there was a high incidence of GVHD that
evertheless correlated with a decreased relapse rate.
ore recently, the same group reported their experi-
nce with Campath-1 in vitro in 216 recipients of T
ell–depleted allogeneic HLA-identical sibling BMT
or hematologic malignancies and nonhematologic
isorders (severe aplastic anemia and hemoglobinop-
thies) [37]. They still found a high incidence of graft
ailure (11%) that was correlated with a higher con-
entration of Campath in vitro and in vivo.
When compared with the results of the Cam-
ath-1H “in the bag” complete T-cell depletion study
f Chakrabarti et al. [39], our results are similar re-
arding the 3-year OS (73.1% versus 80% in our
tudy), the relapse incidence (48.7% versus 43%), and
he incidence of aGVHD grade II (8.7% versus 8.1%),
ut they may compare favorably regarding TRM
19.1% versus 6%). In contrast, the 26% incidence of
limited) cGVHD seemed higher than the 4.2% inci-
08ence in the complete T-cell depletion study. How-
ver, the incidence of post-DLI GVHD in the present
tudy was less frequent and less severe; there was a
0% incidence of grade I GVHD as compared with a
5% incidence of grade II and III.
In conclusion, our protocol might be regarded as a
imple substitute for more sophisticated cell-selection
rocedures because the incidence of severe GVHD
as abrogated without increasing the frequency of
elapse for AML patients. Furthermore, the occur-
ence of molecular resurgence in CML patients was
ostponed to a time when the patients could be suc-
essfully rescued by low-initial-dose DLI. With a
-year OS of 78% (95% CI, 52%-88%), a DFS of
8% (95% CI, 52%-86%), no severe GVHD, and
LIs with only mild morbidities, we believe that this
rotocol ﬁnds a good compromise between the beneﬁ-
ial and harmful effects of allogeneic T cells and, even in
he era of imatinib mesylate [63], makes allogeneic trans-
lantation a valuable therapeutic option for CML.
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